Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women

NCT03172221 is registered in ClinicalTrials.gov with Foundation for Innovative New Diagnostics, Switzerland as lead sponsor.

NCT NCT03172221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03172221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women
Lead sponsor
Foundation for Innovative New Diagnostics, Switzerland
Phase
Observational
Overall status
Completed
Start date
July 25, 2017
Completion date
January 31, 2018
Enrollment
880 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diagnoses disease, plasmodium falciparum, pregnancy malaria